To include your compound in the COVID-19 Resource Center, submit it here.

pSivida reports Phase III data for Durasert in posterior segment uveitis

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) reported additional data from a Phase III trial in 153 patients with chronic, non-infectious posterior

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE